What is it about?
We discovered that autoantibodies to the thyrotropin receptor (TRAb), the key player of a thyroid autoimmune disease named “Graves’ disease”, represent a biomarker helping to predict which patients will develop thyroid dysfunction after receiving alemtuzumab treatment for multiple sclerosis.
Featured Image
Why is it important?
Alemtuzumab is an effective treatment for multiple sclerosis, however it triggers the development of thyroid autoimmunity and dysfunction in more than one third of treated patients. So far only limited predictors of such adverse event are available.
Perspectives
Future studies are needed to develop a comprehensive model including several predictors allowing to anticipate from baseline (before receiving alemtuzumab treatment) which patients are at risk to develop subsequent thyroid dysfunction.
Dr Ilaria IM Muller
Cardiff University
Read the Original
This page is a summary of: Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy; evidence that TRAb may precede thyroid dysfunction by many years, Thyroid, October 2018, Mary Ann Liebert Inc,
DOI: 10.1089/thy.2018.0232.
You can read the full text:
Contributors
The following have contributed to this page
